Shaping the future of medicine with powerful therapeutic and diagnostic platforms

Therapeutics

Novel cancer immunotherapies combining Affimer® biotherapeutics and pre|CISION™ Tumour-activated chemotherapy >

Diagnostics

Development of high performance Affimer®-based diagnostics to improve health outcomes >

Investors

Significant long-term value, growing a pipeline of drug candidates and powerful diagnostic products >

THERAPEUTICS FOCUS

AVA6000 FAP alpha activated prodrug based on the pre|CISIONTM platform.

Read more